Aprepitant inhibits the enzymes involved in the metabolism of pimozide, and is therefore expected to raise pimozide levels, which may result in potentially fatal torsade de pointes arrhythmias. Fosaprepitant, a prodrug of aprepitant, would be expected to interact similarly.
Concurrent use is contraindicated. Caution is needed in the 2 weeks after aprepitant is stopped as there may be some residual enzyme inhibiting activity.
© 2006-2022 Last Updated On: 06/20/2022 (0)
Wait 20 seconds...!!!